

# Hematology

## Division Details

### RESEARCH AND TRAINING DETAILS

Faculty	14
Joint Appointment Faculty	2
Research Fellows and Post Docs	4
Total Annual Grant Award Dollars	\$2,571,145
Total Annual Industry Award Dollars	\$268,725

### CLINICAL ACTIVITIES AND TRAINING

Clinical Fellows	2
Inpatient Encounters	468
Outpatient Encounters	9,131



Row 1: C Quinn, E Mullins, T Kalfa, P Malik, A Hammill, K Ricci

Row 2: P McGann, J Palumbo, R Ware, L Luchtman-Jones, L Shook

[Visit Hematology](#)

## Division Publications

1. McGann PT; Hernandez AG; Ware RE. **Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research.** *Blood.* 2017; 129:155-161.
2. Shaw MA; Kombrinck KW; McElhinney KE; Sweet DR; Flick MJ; Palumbo JS; Cheng M; Esmon NL; Esmon CT; Brill A. **Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice.** *Blood.* 2016; 128:721-731.
3. Bakeer N; James J; Roy S; Wansapura J; Shanmukhappa SK; Lorenz JN; Osinska H; Backer K; Huby AC; Shrestha A. **Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology.** *Proceedings of the National Academy of Sciences of the United States of America.* 2016; 113:E5182-E5191.
4. Key NS; Khorana AA; Mackman N; McCarty OJT; White GC; Francis CW; McCrae KR; Palumbo JS; Raskob GE; Chan AT. **Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group.** *Cancer Research.* 2016; 76:3671-3675.
5. Goyama S; Shrestha M; Schibler J; Rosenfeldt L; Miller W; O'Brien E; Mizukawa B; Kitamura T; Palumbo JS; Mulloy JC. **Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.** *Oncogene:*

Including *Oncogene Reviews*. 2017; 36:2589-2598.

6. Marahatta A; Megaraj V; McGann PT; Ware RE; Setchell KDR. **Stable-Isotope Dilution HPLC-Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples.** *Clinical chemistry*. 2016; 62:1593-1601.
7. Shaw MA; Gao Z; McElhinney KE; Thornton S; Flick MJ; Lane A; Degen JL; Ryu JK; Akassoglou K; Mullins ES. **Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.** *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2017; 37:3776-3788.
8. Pecker LH; Schaefer BA; Luchtman-Jones L. **Knowledge insufficient: the management of haemoglobin SC disease.** *British Journal of Haematology*. 2017; 176:515-526.
9. Dowling MM; Quinn CT; Ramaciotti C; Kanter J; Osunkwo I; Inusa B; Iyer R; Kwiatkowski JL; Johnson C; Rhodes M. **Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke.** *British Journal of Haematology*. 2017; 176:300-308.
10. Chonat S; Chandrakasan S; Kalinyak KA; Ingala D; Gruppo R; Kalfa TA. **Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab.** *British Journal of Haematology*. 2016; 175:744-747.
11. Quinn CT; Paniagua MC; DiNello RK; Panchal A; Geisberg M. **A rapid, inexpensive and disposable point-of-care blood test for sickle cell disease using novel, highly specific monoclonal antibodies.** *British Journal of Haematology*. 2016; 175:724-732.
12. Nottage KA; Ware RE; Aygun B; Smeltzer M; Kang G; Moen J; Wang WC; Hankins JS; Helton KJ. **Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia.** *British Journal of Haematology*. 2016; 175:331-338.
13. Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FWG; Lentz SR; Nemes L; Poulsen LH; Santagostino E. **Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.** *Thrombosis and haemostasis*. 2017; 117:252-261.
14. Quinn CT; Smith EP; Arbabi S; Khera PK; Lindsell CJ; Niss O; Joiner CH; Franco RS; Cohen RM. **Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia.** *American Journal of Hematology*. 2016; 91:1195-1201.
15. Cronin RM; Hankins JS; Adams-Graves P; Thompson AA; Kalinyak K; Byrd J; McClain B; Kassim A; DeBaun M; Treadwell M. **Barriers and facilitators to research participation among adults, and parents of children with sickle cell disease: A trans-regional survey.** *American Journal of Hematology*. 2016; 91:E461-E462.
16. Crosby LE; Joffe NE; Davis B; Quinn CT; Shook L; Morgan D; Simmons K; Kalinyak KA. **Implementation of a Process for Initial Transcranial Doppler Ultrasonography in Children With Sickle Cell Anemia.** *American Journal of Preventive Medicine*. 2016; 51:S10-S16.
17. Cohen RM; Smith EP; Arbabi S; Quinn CT; Franco RS. **Do Red Blood Cell Indices Explain Racial Differences in the Relationship between Hemoglobin A1c and Blood Glucose?.** *The Journal of Pediatrics*. 2016; 176:7-9.
18. Crosby LE; Joffe NE; Peugh J; Ware RE; Britto MT. **Pilot of the Chronic Disease Self-Management Program for Adolescents and Young Adults With Sickle Cell Disease.** *Journal of Adolescent Health*. 2017; 60:120-123.
19. Kalfa TA. **Warm antibody autoimmune hemolytic anemia.** *Hematology-American Society of Hematology Education Program*. 2016; 2016:690-697.
20. Schaefer BA; Flanagan JM; Alvarez OA; Nelson SC; Aygun B; Nottage KA; George A; Roberts CW; Piccone CM; Howard TA. **Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia.** *PLoS one*. 2016; 11:e0164364.
21. Mineo C; Lanier L; Jung E; Sengupta S; Ulrich V; Sacharidou A; Tarango C; Osunbunmi O; Shen YM; Salmon JE. **Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis.** *PLoS one*. 2016; 11:e0158757.

22. Niss O; Chonat S; Dagaonkar N; Almansoori MO; Kerr K; Rogers ZR; McGann PT; Quarmyne MO; Risinger M; Zhang K. **Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis.** *Blood Cells, Molecules, and Diseases.* 2016; 61:4-9.
23. Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE. **Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.** *Haemophilia.* 2017; 23:238-246.
24. Lim MY; Cheng D; Aschman D; Dunn A; Ahuja S; Carpenter SL; Davis JA; French J; Gruppo R; Knoll C. **Radionuclide synovectomy in patients with bleeding disorders: a review of malignancy and myeloproliferative neoplasms from the ATHNdataset.** *Haemophilia.* 2017; 23:e160-e162.
25. Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE. **Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.** *Haemophilia.* 2016; 22:e251-e258.

## Grants, Contracts, and Industry Agreements

### Annual Grant Award Dollars

Investigator	Title	Sponsor	ID	Dates	Amount
Ralph A Gruppo, MD	Hemophilia And Thrombosis Center	Cascade Hemophilia Consortium (Hemophilia Foundation of Michigan)	Gruppo, CHC/HFM	06/01/2003 - 05/31/2018	\$114,597
Ralph A Gruppo, MD	Community Counts: Public Health Surveillance for Bleeding Disorders	Ctr for Disease Control and Prevention (Hemophilia Foundation of Michigan)	10U27DD000862	10/01/1997 - 09/29/2016	\$28,000
Lisa M Shook	Sickle Treatment and Outcomes Research in the Midwest - Treatment Demonstration Project	Health Resources & Services Admin	U1EMC27863	09/01/2014 - 08/31/2017	\$832,152
Russell Ware, MD, PhD	Endothelialized Microfluidics for Sickle Cell Disease Research & Drug Discovery	National Institutes of Health (Emory University)	R01 HL121264	01/01/2014 - 12/31/2018	\$18,372
Russell Ware, MD, PhD	Genetic Modifiers of Transfusional Iron Overload	National Institutes of Health (Baylor College of Medicine)	R21HL123641	08/01/2015 - 07/31/2017	\$17,979
Patrick McGann, MD, MS	Therapeutic Response Evaluation and Adherence Trial: A Prospective Study of Hydroxyurea for Children with Sickle Cell Anemia	National Institutes of Health	K23 HL128885	09/01/2015 - 05/31/2020	\$188,563
Joseph S Palumbo, MD	Hemostatic Factors Drive Prostate Cancer Pathogenesis	National Institutes of Health	R01 CA193678	04/15/2016 - 03/31/2021	\$356,850

Russell Ware, MD, PhD	Genetic Variants Influencing the Phenotypic Expression of Sickle Cell Anemia	Doris Duke Charitable Foundation	2015132	09/01/2015 - 08/31/2018	\$162,000
Joseph S Palumbo, MD	Coagulation Factors as Modifiers of the Colon Cancer Microenvironment	National Institutes of Health	R01 CA204058	04/05/2016 - 03/31/2021	\$356,850
Lisa M Shook	Cincinnati Sickle Cell Project	Ohio Department of Health	0310011SK1017	07/01/2016 - 06/30/2021	\$125,957.40
Harry Lesmana, MD	Elucidating the Role of RalGDS Pathway in Erythropoiesis	American Society of Hematology	Lesmana, Harry, ASH	07/01/2016 - 06/30/2017	\$5,000
Patrick McGann, MD, MS	Genetic and Biological Determinants of Immune Thrombocytopenia: ITP Consortium of North America (ICON) Research Sample Bank	Texas Children's Hospital	McGann, Pat, TCH	07/01/2016 - 06/30/2020	\$6,250
Russell Ware, MD, PhD	Baby Hug Follow-up Study II Core Laboratory	National Institutes of Health (New England Research Institutes)		01/01/2016 - 05/05/2017	\$266,950
Cristina Tarango, MD	Region V East Comprehensive Care Network for Bleeding Disorders	Maternal & Child Health Bureau (Hemophilia Foundation of Michigan)	H30 MC24047	06/01/2016 - 05/31/2021	\$22,000
Cristina Tarango, MD	Community Counts: Public Health Surveillance for Bleeding Disorders	Ctr for Disease Control and Prevention (Hemophilia Foundation of Michigan)	U27 DD001155	09/30/2016 - 09/29/2020	\$27,250
Cristina Tarango, MD	Prospective Evaluation of the Duration of Therapy for Thrombosis in Children (Kids- DOTT)	National Institutes of Health (All Childrens Resesearch Inst., Inc.)	U01 HL130048	01/11/2017 - 06/30/2021	\$6,374
Adrienne Hammill, MD	Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants with Infantile Hemangioma	National Institutes of Health (Duke University)	HHSN275201000003I	01/01/2017 - 09/28/2017	\$11,000
Cristina Tarango, MD	ATHN Data Quality Counts	American Thrombosis & Hemostatis Network	AA108	07/01/2016 - 06/30/2017	\$7,000
Adrienne Hammill, MD	Phase 2 Study of Vincristine vs. Sirolimus for the Treatment of High Risk Kaposiform Hemangioendothelioma	Food and Drug Administration (Children's Hospital Boston)	R01 FD004363	09/01/2016 - 08/31/2017	\$13,001

Cristina Tarango, MD	Hemophilia Alliance Home Infusion Guidebook	The Hemophilia Alliance Foundation	Tarango, C, HAF	03/01/2017	\$5,000
				-	
				02/28/2018	

**Total Annual Grant Award Dollars**

**\$2,571,145.40**

## Annual Industry Award Dollars

Investigator	Industry Sponsor	Amount
Charles T Quinn, MD	Global Blood Therapeutics	\$36,725
Ralph A Gruppo, MD	Baxter Healthcare Corp.	\$45,000
Ralph A Gruppo, MD	Novo Nordisk Pharmaceuticals	\$17,000
Russell Ware, MD, PhD	Bristol -Myers Squibb	\$170,000
<b>Total Annual Industry Award Dollars</b>		<b>\$268,725</b>

---